Finally, the role of PARP inhibition as a therapeutic strategy may be efficacious in a wider range of myeloid malignancies characterized by DNA damage repair defects, including IDH1/2-AML, FLT3-ITD-AML, splicing factor mutant AML, and AML1-ETO rearranged AML (49). The gene discussed is RUNX1; the disease is acute myeloid leukemia.